(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/278326 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:
PCT/US2022/035122

(22) International Filing Date:
27 June 2022 (27.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/215,901 28 June 2021 (28.06.2021) US

(71) Applicant: **BLUEPRINT MEDICINES CORPORATION** [US/US]; 45 Sidney Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **WILSON, Douglas**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **BIFULCO, JR., Neil**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **BROOIJMANS, Natasja**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **KIM, Joseph L.**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **PEROLA, Emanuele**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **RAMSDEN, Philip D.**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **VARGAS, Richard**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **WENGLOWSKY, Steven Mark**; c/o 45 Sidney Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **KANEKO, Miho** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor, Boston, Massachusetts 02210 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/278326 A1

(54) Title: CDK2 INHIBITORS



(I)

(57) Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.